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Objective: In the interest of exploring alternatives to warfarin, we tested the hypoth-
esis that clopidogrel combined with aspirin is effective for thromboprophylaxis of
mechanical valves using a swine model.
Methods: Adult swine underwent heterotopic implantation of a modified bileaflet
mechanical valved conduit bypassing the ligated, native descending thoracic aorta.
Animals were randomized to no anticoagulation (n5 7), 175 U/kg dalteparin admin-
istered subcutaneously twice daily (n 5 9), 325 mg of aspirin (n 5 6), 75 mg of
clopidogrel (n 5 6), or 325 mg of aspirin and 75 mg of clopidogrel daily (n 5 6)
and survived for 30 days. Additionally, 11 animals were randomized to no anticoagu-
lation (n 5 5) or 325 mg of oral aspirin and 75 mg of clopidogrel daily (n 5 6) and
survived for 150 days.
Results: At 30 days, we observed 2166 270 mg of thrombus for the no anticoagula-
tion group, 536 91 mg for the dalteparin group, 336 23 mg for the aspirin group, 25
6 10 mg for the clopidogrel group, and 176 9 mg for the combined aspirin and clo-
pidogrel group, respectively (P , .01 for clopidogrel and aspirin vs no anticoagula-
tion). At 150 days, we observed 2236 200 mg of thrombus for the no anticoagulation
group and 4 6 4 mg for the aspirin and clopidogrel group (P 5 .02). Mean platelet
deposition on the valve was 4.1 3 109 6 3.6 3 109 for the no anticoagulation and
6.813 1076 1.43 108 for the combined aspirin and clopidogrel groups, respectively
(P 5 .03). No major hemorrhagic events were observed.
Conclusions: Effective short- and long-term thromboprophylaxis of mechanical
valves can be achieved by using dual-antiplatelet therapy in this porcine model. Pro-
spective human trials should be conducted with combination aspirin and clopidogrel
as an alternative to warfarin in patients with bileaflet mechanical aortic valves.
T
here is considerable interest in using new anticoagulation strategies for
patients with mechanical heart valves because of the hemorrhagic and throm-
boembolic complications associated with long-term anticoagulation with war-
farin.1 Several new classes of medications have been developed for long-term
anticoagulation2,3 and have been studied clinically for conditions such as atrial fibril-
lation4 and the prevention and treatment of deep venous thrombosis after orthopedic
surgery.5,6
Potent antiplatelet agents, such as clopidogrel, are among these newer agents.
Clopidogrel is an orally administered adenosine diphosphate (ADP) P2Y12 receptor
antagonist, which, in conjunction with aspirin, has demonstrated clinical benefit for
a variety of cardiovascular conditions, including myocardial infarction7,8 and reduc-
tion of in-stent restenosis after coronary artery stenting.9,10
Dual therapywith aspirin and clopidogrel may have enhanced inhibition because each
agent inhibits platelets through different pathways, the cyclooxygenase/thromboxane and
ADP pathways, respectively. Clopidogrel combined with aspirin, however, has not been
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extensively studied in vivo for thromboprophylaxis of me-
chanical heart valves. We hypothesized that dual-antiplatelet
therapy with aspirin and clopidogrel would be as effective as
heparin for thromboprophylaxis of mechanical heart valves
in swine.
Materials and Methods
Animal Model and Study Design
Approval for this study was obtained from the Animal Care and
Use Committee of the Mayo Foundation. Adult swine underwent
heterotopic mechanical aortic valve placement, as previously
described.11 Briefly, the model consists of a modified bileaflet aor-
tic valved conduit (St Jude Masters Series; St Jude, Minneapolis,
Minn), which bypasses the ligated native descending thoracic
aorta. This enables somatic blood flow distal to the left subclavian
artery to pass across the mechanical valve in the newly constructed
neoaortic (Figure 1). For the acute (30-day) study, we used the
low-molecular-weight heparin dalteparin as the standard for antico-
agulation because of the difficulty in maintaining a therapeutic
window with warfarin in swine.12 For the chronic (150-day) study,
the control group consisted of animals not receiving any
anticoagulation.
Acute Study
Thirty-four animals were randomized into one of 5 treatment arms
of postoperative anticoagulation. These groups consisted of no anti-
coagulation (n 5 7), 175 U/kg dalteparin (Eisai/Pfizer, Inc, Wood-
cliff, NJ) administered subcutaneously twice daily (n 5 9), 325 mg
of aspirin (Bayer, Inc, Pittsburg, Pa) administered by mouth daily
(n 5 6), 75 mg of clopidogrel (Bristol-Meyers Squibb/Sanofi Phar-
maceuticals, New York, NY) administered by mouth daily (n5 6),
or a combination of 325 mg of aspirin and 75 mg of clopidogrel
administered by mouth daily (n 5 6). Animals received their as-
signed treatment medication beginning on postoperative day 1.
Of note, data from 3 animals for both the no anticoagulation and
dalteparin groups were pooled with data from previous experi-
ments.13 The dose of dalteparin (175 U/kg twice daily) was calcu-
lated from dosing studies performed in swine during a previous
study.13
Chronic Study
Animals were randomly assigned to receive either no anticoagula-
tion (n 5 5) or the combination of 325 mg of aspirin and 75 mg
of clopidogrel administered by mouth daily (n 5 6).
Valve Thrombus
The primary end point of this study was the amount of valve throm-
bus after 30 days for the acute study and after 150 days for the
chronic study. Animals were sacrified after achievement of general
anesthesia after systemic heparinization, at which time valve throm-
bus was measured and reported in milligrams as the mean 6 stan-The Journal of Thodard deviation. Only thrombus on the valve was measured, and
this was done blinded to the treatment arm.
Hemorrhagic and Thromboembolic Complications
Secondary end points were obvious or occult hemorrhagic or throm-
boembolic complications. Animals were observed daily for hemor-
rhagic complications (obvious gastrointestinal hemorrhage) and for
thromboembolic complications (neurologic deficits or lower ex-
tremity or bowel ischemia). Additionally, kidneys were grossly in-
spected at the time of death to evaluate for gross embolic events.
In the acute study occult hemorrhage was sought for as animals un-
derwent serial blood draws to measure serum hemoglobin and fecal
hemoglobin concentrations. Occult hemorrhagic events were
defined as a decrease in the serum hemoglobin level of more than
2 g/dL or an abnormally high fecal hemoglobin level (.2 mg hemo-
globin/g of stool).
Platelet Aggregation Studies
In the acute study platelet aggregation studies were performed by
using platelet-rich plasma with a turbidimetric method, with
a whole-blood aggregometer in optical mode (Chrono-log, Haver-
town, Pa). Arachidonic acid (1.0 mmol/L) and ADP (10 mmol/L)
were used as agonists for aggregation, as described previously,14
to document platelet inhibition to aspirin and clopidogrel, respec-
tively.
Figure 1. Heterotopic aortic valve model demonstrating the mod-
ified valved conduit (St Jude Masters Series, St Jude Medical) as
it bypasses the ligated native descending thoracic aorta. Used
with permission from the Mayo Foundation for Medical Education
and Research.racic and Cardiovascular Surgery c Volume 136, Number 4 909
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Platelet deposition on the mechanical prosthesis in the chronic study
was assessed by using autologous platelet labeling with 111indium,
as previously described.8,9 Briefly, after explantation of the valve, it
was placed into a scintillation radiocounter (Capintec, Inc, Ramsay,
NJ). Background radioactivity and the amount of radioactivity from
two 10-mL tubes of blood were obtained at the time of animal death.
By using the animal’s platelet count and radioactivity obtained from
the tubes of blood, the average amount of radioactivity per platelet
was determined. This was used to calculate the number of platelets
on the prosthesis by using the following equation: Number of plate-
lets on valve prosthesis5 Valve radioactivity/Platelet radioactivity.
Statistical Analysis
Valve thrombus and number of platelets deposited on the valve
prosthesis reported in milligrams as the mean 6 standard deviation
were treated as continuous variables. Mean valve thrombus and
maximum platelet aggregation among the groups in the acute study
were compared by using the Kruskal–Wallis test for heterogeneity.
Mean valve thrombus for the antiplatelet groups was compared with
that for the dalteparin group by using the Wilcoxon rank sum test.
Results
Acute Study
There were no perioperative deaths, and all animals survived
for 30 days without obvious hemorrhagic or ischemic com-
plications. One animal in the clopidogrel group had infec-
tious valvular vegetation found at death (histologically
confirmed, not shown) and was excluded from the analysis
of mean thrombus weight. At the time of death, the mean
thrombus weight for the groups was 216 6 270 mg for the
no anticoagulation, 53 6 91 mg for the dalteparin, 33 6 23
mg for the aspirin, 25 6 10 mg for the clopidogrel, and 17
6 9 mg for the combined aspirin and clopidogrel groups,
respectively (Figure 2, A). This represented a 10-fold
decrease in mean valve thrombus for the combined aspirin
and clopidogrel group than that seen in the no anticoagulation
group (P , .01). Although not statistically significant, we
observed a trend in decreased thrombus formation in the
combined aspirin and clopidogrel group compared with the
other antiplatelet arms, suggesting a synergistic antiplatelet
effect (P 5 .5; Figure 2, B). Maximal platelet aggregation
in platelet-rich plasma to ADP (10 mmol/L) decreased signif-
icantly with combination antiplatelet therapy with aspirin and
clopidogrel (P 5 .03), as shown in Figure 3, A. Representa-
tive postmortem photographs of explanted valves from the no
anticoagulation and combined aspirin and clopidogrel groups
are shown in Figure 4, A and B.
There were no obvious hemorrhagic or thromboembolic
complications. However, occult hemorrhagic complications
were observed in 3 animals. One animal receiving dalteparin
experienced an occult decrease in serum hemoglobin level
from 12.4 to 6.5 g/dL. Two animals had abnormally high
fecal hemoglobin assays of 3.5 and 15.6 mg hemoglobin/g
of stool, from the aspirin and dalteparin groups, respectively.910 The Journal of Thoracic and Cardiovascular Surgery c OChronic Study
There were no perioperative deaths, but 2 animals receiving
aspirin and clopidogrel did not survive 150 days. One animal
had signs of sepsis and was sacrified on postoperative day 85.
Infectious vegetations were seen on the valve (confirmed
with histology, not shown). This animal was not included
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Figure 2. A, Mean valve thrombus (in milligrams6 standard error
of the mean) for each of the 5 arms at 30 days (P 5 .02). B, Mean
valve thrombus for the 3 antiplatelet arms at 30 days (P5 .5). Qual-
itatively, animals receiving combined aspirin and clopidogrel had
the least amount of valve thrombus. C, Mean valve thrombus (in
milligrams 6 standard error of the mean) for the two 150-day sur-
vivor groups: no anticoagulation and combined aspirin and clopi-
dogrel (P5 .02). n, Number of animals; no AC, no anticoagulation;
ASA, aspirin.ctober 2008
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CDin the analysis because of the inability to separate valve
thrombus from vegetation. The other animal was found
dead on postoperative day 66. Necropsy was not informative
as to the cause of death because thoracic, intra-abdominal,
and retroperitoneal organs appeared normal; thus a lethal ar-
rhythmia was presumed. When the valve prosthesis and aorta
were examined, only 10.5 mg of thrombus was identified on
the valve and was included in the analysis. No obvious hem-
orrhagic or thromboembolic events were observed in the
surviving 9 animals.
At 150 days, mean valve thrombus was lower for the anti-
platelet group. Mean thrombus was 2236 200 mg for the no
anticoagulation group and 46 4 mg for the aspirin and clopi-
dogrel groups (P 5 .02), as shown in Figure 2, C. Similarly,
themean number of platelets deposited on the valve prosthesis
was less for the antiplatelet group. The mean number of plate-
lets deposited on the valves was 4.13 1096 3.63 109 for the
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Figure 3. A, Cumulative results of aggregation in response to stim-
ulus with 10 mmol/L adenosine diphosphate in platelets obtained
from swine receiving antiplatelet therapy postoperatively. Data
are presented as means 6 standard error of the mean. Maximum
platelet aggregation decreased significantly with combination
antiplatelet therapy (P5 .03). B, Mean number of platelets depos-
ited on valves for the 2 groups: no anticoagulation and combined
aspirin and clopidogrel (P 5 .03). ASA, Aspirin; n, number of ani-
mals; No AC, no anticoagulation.The Journal of Thorno anticoagulation group and 6.813 1076 1.43 108 for the
combined aspirin and clopidogrel group (P5 .03), as shown
in Figure 3, B. Representative photographs of valve prosthe-
ses at 150 days are shown in Figure 4, C and D.
Discussion
The principal finding of this study is that antiplatelet agents
are effective for thromboprophylaxis of mechanical heart
valves in swine. At short-term follow-up, treatment with as-
pirin and clopidogrel was as effective as treatment with hep-
arin and led to the least amount of valve thrombus at 30 days.
The efficacy of combined antiplatelet therapy was confirmed
during long-term follow-up at 150 days.
The idea of using antiplatelet agents in place of warfarin
for mechanical heart valve thromboprophylaxis is not new.
Ribeiro and colleagues15 and Hartz and associates16 were
among the first to report the use of combination antiplatelet
agents (aspirin and dipyridamole) for thromboprophylaxis
of bileaflet mechanical valves. They reported unacceptably
high rates of valve thrombosis at 7.5% and 4.6%, respec-
tively. With this, enthusiasm for antiplatelet therapy dimin-
ished until more potent antiplatelet agents, such as
clopidogrel, were introduced for treating cardiovascular
diseases.17
Large clinical trials with combination therapy of aspirin
and clopidogrel have been performed to test the hypothesis
that combination antiplatelet therapy leads to more global in-
hibition of platelet function and improved clinical outcomes.
Studies such as the Clopidogrel in Unstable Angina to Pre-
vent Recurrent Events; Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization, Management, and
Avoidance; and Clopidogrel Aspirin Stent International Co-
operative trials have demonstrated the clinical benefit of com-
bined aspirin and clopidogrel over that of aspirin alone in the
prevention of vascular events, cardiovascular events, and
coronary stent thrombosis, respectively.2,10,18 Mechanisti-
cally, these results might be predicted because aspirin inhibits
platelet function by blocking production of thromboxane A2
through inhibition of the cyclooxygenase I enzyme. Clopi-
dogrel, on the other hand, inhibits platelet function through
an alternative pathway by inhibiting platelet ADP receptors.
Our qualitative observation of decreased valve thrombus and
quantitative observation of decreased platelet aggregation in
animals treated with combined aspirin and clopidogrel fur-
ther support this hypothesis (Figures 2 and 3).
The safety of antiplatelet therapy for mechanical heart
valve thromboprophylaxis remains controversial. There is
limited information on combination of antiplatelet therapy
for mechanical valve thromboprophylaxis from clinical trials.
Schlitt and coworkeres19 studied the combination of aspirin
and clopidogrel in 11 patients undergoing aortic valve re-
placement with several types of mechanical prostheses.
This trial was stopped prematurely after a patient with a his-
tory of pulmonary embolism experienced aortic valveacic and Cardiovascular Surgery c Volume 136, Number 4 911
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CDFigure 4. Postmortem photographs of
explanted valves. A, Representative
valve from the no anticoagulation group
at 30 days. B, Representative valve from
the combined aspirin and clopidogrel
group at 30 days. C, Representative
valve from the no anticoagulation group
at 150 days. D, Representative valve
from the combined aspirin and clopi-
dogrel group at 150 days.thrombosis. Inadequate platelet inhibition and an underlying
prothrombotic state are possible explanations for this adverse
event in light of increasing evidence of aspirin resistance and
considerable interindividual variability in response to stan-
dard doses of clopidogrel.20 Aspirin resistance has been re-
ported in up to 35% of patients,21 although its prevalence
might be overestimated.22,23 Additionally, studies of platelet
function in aspirin-resistant platelets demonstrate increased
sensitivity to other platelet activators, such as ADP.24 Platelet
function was not reported by Schlitt and coworkers,19 and it
is possible that a combination of all 3 factors, aspirin resis-
tance,23 hypersensitivity to ADP stimulation,24 and interpa-
tient variability to clopidogrel,20 in addition to an
underlying hypercoagulable state leading to the patient’s
prior pulmonary embolism, might have led to the valve
thrombosis. Most recently, one of the authors (RGR) has
more than 5 years of experience treating patients after iso-
lated aortic valve replacement with mechanical prostheses
with only combined aspirin and clopidogrel,25,26 suggesting
the adverse event observed in the trial by Schlitt and co-
workers9 might be quite rare. Regardless, documentation of
adequate platelet inhibition as an inclusion criterion would
seem essential when considering antiplatelet agents for
thromboprophylaxis on mechanical valvular prostheses in
human subjects and should be part of any future clinical trial.
It is not clear, however, whether platelet aggregometry, as we912 The Journal of Thoracic and Cardiovascular Surgery c Octoused, or other techniques, such as thromboelastography,27 are
best suited to determine platelet inhibition.
The risk of adverse bleeding events while using antiplate-
let agents for thromboprophylaxis is also a potential concern.
In contrast to clinical trials,2 we did not observe increased
rates of hemorrhagic complications in animals receiving
combined aspirin and clopidogrel therapy. We did, however,
observe 3 occult hemorrhagic events in animals receiving
dalteparin (n5 2) and aspirin (n5 1) in the acute study. Sim-
ilarly, the 2 deaths in the chronic study were not related to
antiplatelet therapy. Whether the low rates of hemorrhagic
complications we observed during our studies will persist
over the longer-term follow-up is unknown.
Replacing warfarin with antiplatelet agents, such as clopi-
dogrel and aspirin, for thromboprophylaxis of mechanical
heart valves has important potential clinical implications.
First, clopidogrel might be safer than warfarin because of
more predictable dose response and fewer drug interactions.
Its action also is less affected by dietary changes, which are
known to be a problem with warfarin.28 Additionally, its ac-
tion is less affected by antiplatelet therapy might be more
cost-effective than warfarin in that treatment does not require
frequent and expensive international normalized ratio moni-
toring. Finally, oral antiplatelet agents might offer an advan-
tage over intravenous or injectable heparins for short-term
bridging of patients to full anticoagulation (with warfarin).ber 2008
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large-animal data. The remaining questions relate to clinical
trial design. Clinical trials could be designed to evaluate
antiplatelet therapy as either initial thromboembolism
prophylaxis in the immediate postoperative period or as
maintenance of thromboembolism prophylaxis after 3
months of traditional anticoagulation (warfarin) therapy.
Enrolling patients into a trial immediately after valve re-
placement surgery would attempt to answer the more robust
or complicated question of prophylaxis during the period of
greatest risk of thromboembolic events.10-13 In contrast, en-
rolling patients after 3 months of presumably more intense
therapy (warfarin) might be a safer approach for evaluating
dual-antiplatelet therapy because the period of greatest risk
of thromboembolic events would have already passed.
Perhaps the most reasonable approach would be to try to
answer these 2 questions sequentially. The first trial could
study combined aspirin and clopidogrel as maintenance of
anticoagulation after conventional treatment (warfarin). If
the results are promising and safe, a second ‘‘higher-risk’’
trial could enroll patients immediately after surgical inter-
vention.
The primary limitation of the acute study was that the
comparison group in the swine model was dalteparin rather
than warfarin, which is used clinically. We chose dalteparin
instead of warfarin because of the well-established difficulty
of maintaining therapeutic anticoagulation in swine.12 The
primary limitation in the chronic study was the small sample
size and the lack of a full-anticoagulation control group.
These were unavoidable because of the prohibitive cost of
5-month-survival animal studies and the cumbersome nature
of twice-daily low-molecular-weight heparin administration,
which would have been required for a heparin control group.
Although greater numbers of animals would have been ben-
eficial, the tight standard deviation observed in the mean
valve thrombus weight among animals treated with aspirin
and clopidogrel is encouraging and suggests that this chronic
model accurately represents the biologic phenomenon we are
trying to study.
Conclusions
Antiplatelet therapy with the combination of aspirin and clo-
pidogrel is effective for short- and long-term thromboprophy-
laxis of mechanical heart valves. Preclinical animal data now
exist and are the foundation for clinical trials evaluating anti-
platelet agents as an alternative to warfarin in appropriately
selected patients with bileaflet mechanical valve aortic
valves.
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